FINWIRES · TerminalLIVE
FINWIRES

财报季和德黑兰提案提振亚洲股市

By

-- 周一,亚洲股市普遍上涨,科技股走强以及媒体报道称德黑兰已提出重新开放霍尔木兹海峡的提议提振了市场情绪。北京方面公布的总体良好的工业企业盈利报告也提振了市场情绪。 上海和东京股市收涨,香港股市小幅下跌。其他地区性交易所大多收高。 在日本,日经225指数开盘走势平稳,但最终收涨1.4%,创下历史新高。强劲的盈利报告抵消了避险情绪的影响。 日经225指数上涨821.18点,收于60,537.36点,首次突破60,000点大关。尽管下跌个股数量超过上涨个股,比例为129比94。 工业机器人制造商发那科(Fanuc)领涨,涨幅达16%,而中外制药(Chugai Pharmaceutical)下跌15.8%,两家公司的股价波动均源于财报发布。 香港恒生指数收跌0.2%,受房地产股拖累。 恒生指数下跌52.42点,收于25,925.65点,下跌个股数量超过上涨个股,比例为53比36。恒生科技指数当日上涨0.8%,而内地房地产指数下跌0.7%。 中芯国际领涨,涨幅达6.1%,而国药集团下跌3.8%。 内地方面,上证综指上涨0.2%,收于4,086.34点。 经济新闻方面,国家统计局数据显示,3月份中国工业企业利润同比增长15.8%,主要得益于民营企业的强劲增长。该机构的调查对象为年营业额超过290万美元的企业。 其他地区交易所方面,韩国综合股价指数上涨2.2%。台湾加权指数(TWSE)上涨1.8%;澳大利亚ASX 200指数下跌0.2%;新加坡海峡时报指数下跌0.6%;泰国SET指数上涨1.6%。孟买Sensex指数在尾盘交易中上涨0.8%。 MSCI亚太地区所有国家指数当日上涨1.2%。

Related Articles

Treasury

Scotiabank Previews This Week's February and Preliminary March GDP for Canada

Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.

$$CXY
Australia

Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing

Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%

$VICR
Australia

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%

$BMRN$FOLD